CA2900526C - Compositions and their use to treat heart failure with preserved injection fraction (hfpef) - Google Patents

Compositions and their use to treat heart failure with preserved injection fraction (hfpef) Download PDF

Info

Publication number
CA2900526C
CA2900526C CA2900526A CA2900526A CA2900526C CA 2900526 C CA2900526 C CA 2900526C CA 2900526 A CA2900526 A CA 2900526A CA 2900526 A CA2900526 A CA 2900526A CA 2900526 C CA2900526 C CA 2900526C
Authority
CA
Canada
Prior art keywords
nitrate
inorganic
heart failure
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2900526A
Other languages
English (en)
French (fr)
Other versions
CA2900526A1 (en
Inventor
Julio A. Chirinos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2900526A1 publication Critical patent/CA2900526A1/en
Application granted granted Critical
Publication of CA2900526C publication Critical patent/CA2900526C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
CA2900526A 2013-02-07 2014-02-07 Compositions and their use to treat heart failure with preserved injection fraction (hfpef) Active CA2900526C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761863P 2013-02-07 2013-02-07
US61/761,863 2013-02-07
PCT/US2014/015300 WO2014124256A1 (en) 2013-02-07 2014-02-07 Methods of treating heart failure

Publications (2)

Publication Number Publication Date
CA2900526A1 CA2900526A1 (en) 2014-08-14
CA2900526C true CA2900526C (en) 2021-05-04

Family

ID=51300154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2900526A Active CA2900526C (en) 2013-02-07 2014-02-07 Compositions and their use to treat heart failure with preserved injection fraction (hfpef)

Country Status (6)

Country Link
US (1) US20150366901A1 (enExample)
EP (1) EP2953631A4 (enExample)
JP (1) JP6441818B2 (enExample)
CN (1) CN105101977A (enExample)
CA (1) CA2900526C (enExample)
WO (1) WO2014124256A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134585A1 (en) 2013-02-28 2014-09-04 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics
CN110461171A (zh) 2017-03-23 2019-11-15 美生盐有限公司 含甜菜根的组合物
WO2018195537A1 (en) * 2017-04-21 2018-10-25 Northeast Ohio Medical University Vasodilators for treatment of heart failure
WO2019055704A1 (en) * 2017-09-13 2019-03-21 Thermolife International, Llc ENRICHED ROOT POWDER PRODUCTS AND METHODS OF MAKING SAME
FI128489B (en) 2018-10-01 2020-06-15 Precordior Oy Equipment for generating information indicating cardiac abnormality

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004884A2 (en) * 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
CA3187624A1 (en) * 2007-02-26 2008-09-04 Heartbeet Ltd. New use of nitrites and nitrates and compositions containing these
US20120214818A1 (en) * 2009-09-11 2012-08-23 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en) * 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
GB201020811D0 (en) * 2010-12-08 2011-01-19 Solvotrin Innovations Ltd Compounds
US20140112983A1 (en) * 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
WO2014134585A1 (en) * 2013-02-28 2014-09-04 Aires Pharmaceuticals, Inc. Inorganic nitrite to improve cardiopulmonary hemodynamics

Also Published As

Publication number Publication date
CN105101977A (zh) 2015-11-25
JP6441818B2 (ja) 2018-12-19
US20150366901A1 (en) 2015-12-24
JP2016507570A (ja) 2016-03-10
EP2953631A4 (en) 2017-03-01
EP2953631A1 (en) 2015-12-16
CA2900526A1 (en) 2014-08-14
WO2014124256A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
Papadia et al. Citrulline in health and disease. Review on human studies
Woessner et al. Dietary nitrate supplementation in cardiovascular health: an ergogenic aid or exercise therapeutic?
Kim et al. Acute ingestion of citrulline stimulates nitric oxide synthesis but does not increase blood flow in healthy young and older adults with heart failure
Kenjale et al. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease
Kawano et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery
Serhiyenko et al. Diabetic cardiac autonomic neuropathy
CA2900526C (en) Compositions and their use to treat heart failure with preserved injection fraction (hfpef)
HUE032486T2 (en) An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
Khanna et al. The management of hyperkalemia in patients with cardiovascular disease
US20160303177A1 (en) Nutritional supplement
US7629329B2 (en) Method for increasing muscle mass and strength through administration of adenosine triphosphate
Strugaru et al. Metformin induced lactic acidosis–particularities and course
US20140141069A1 (en) Beta-guanidinopropionic acid for the treatment of hypertension
JP6258943B2 (ja) Ｈｍｂおよびａｔｐの組成物ならびに使用方法
US20050153020A1 (en) Composition comprising phosphate
Lee-Chiong et al. The heart in the stable COPD patient
US10888576B2 (en) Composition of HMB and ATP and methods of use
Turpin Therapeutic role of dietary nitrates on cardiorespiratory function in cancer survivors
Dumler et al. Optimal dialysis for the end-stage renal disease patient with cardiovascular disease
Clarke Impact of Creatine Supplementation on Vascular Endothelial Function, Blood Flow and Functional Capacity in Older Adults
Seto Acute Ketone Ester Supplementation On The Neuro-Cardiovascular Response To Stress In Humans
Woessner BEET-HF: The Effects of Dietary Inorganic Nitrate Supplementation on Aerobic Exercise Performance, Vascular Function, Cardiac Performance and Mitochondrial Respiration in Patients with Heart Failure with Reduced Ejection Fraction
HK1217087B (zh) Hmb和atp的组合物及使用方法
Kim Acute Effects of Dietary Nitrate Supplementation in Postmenopausal Women
EP4663203A1 (en) Combination of sglt2 inhibitor and menthol and use thereof in treatment of heart disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190207